Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good day everyone and welcome to today’s Avadel Pharmaceuticals ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Looking ahead, we decided to maintain our buy rating target. The company delivered Q3 2024 sales of €277.9 million ... the ...

In March, Cigna and its pharmacy ... to target HCPs with high plan mix with poor access, rather than using it broadly. Ultimately this allows more precise control of field sales targeting to ...

Tuesday closed down -0.29%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.86%, and the Nasdaq 100 Index ($IUXX ...

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...

However, how many pharma executives working in sales or marketing are taught to understand buying processes? The biggest single change in pharma over the past decade has been the change in buying.

2024 Healthcare & Pharmaceuticalscategory Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales November 12, 2024 Healthcare & Pharmaceuticalscategory AstraZeneca lifts 2024 ...

Brand recognition is key in this unit, as evidenced by the company's iconic Aspirin, which continues to post strong sales even after decades of ... Similar to other large pharmaceutical companies, ...